Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02073487
Title Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab With Lapatinib and Paclitaxel
Recruitment Completed
Gender female
Phase Phase II
Variant Requirements No
Sponsors The Methodist Hospital System
Indications

Her2-receptor positive breast cancer

Therapies

Paclitaxel

Ado-trastuzumab emtansine + Lapatinib

Lapatinib + Trastuzumab

Nab-paclitaxel

Age Groups: adult
Covered Countries USA


No variant requirements are available.